Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib plus platinum-pemetrexed for uncommon EGFR-mutated advanced non-small cell lung cancer
jRCTs011240066Phase 2Recruiting
- Sponsor
- North East Japan Study Group
- Start
- Mar 2025
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osimertinib, cisplatin, carboplatin and pemetrexed in non-small cell lung cancer (NSCLC), sponsored by North East Japan Study Group. Primary endpoint: Objective response rate. Started Mar 2025; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs011240066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs011240066.